Valuation: Positron Corporation

Market Cap 55.18M 48.51M 45.16M 41.47M 77.87M 5.29B 78.9M 537M 210M 2.61B 207M 203M 9.03B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 54.04M 47.51M 44.23M 40.62M 76.27M 5.18B 77.27M 526M 205M 2.56B 203M 199M 8.85B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day-5.36%
1 week-7.02%
Current month-15.43%
1 month-17.19%
3 months-17.62%
6 months-6.47%
Current year-4.79%
1 week 1.45
Extreme 1.45
1.7
1 month 1.43
Extreme 1.43
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-5.36%-7.02%-17.62%+6.71% 55.18M
+0.62%+0.07%-19.43%-24.90% 13.29B
+1.01%+2.98%+44.55%-10.99% 3.94B
+0.20%-2.19%+66.18%+119.03% 1.21B
+3.42%-0.79%-42.20%-61.16% 1.14B
+3.20%+0.85%-40.72%-48.02% 1.07B
+2.53%-2.02%-46.34% - 900M
+12.30%+3.11%+35.27%+95.70% 450M
+2.31%-1.56%+52.76% - 324M
-1.39%-4.47%-60.18%+211.16% 257M
Average +1.88%-1.16%-2.77%+35.94% 2.26B
Weighted average by Cap. +1.22%-2.87%-5.28%-11.85%

Financials

2024 2025
Net sales 588K 516K 481K 442K 829K 56.34M 840K 5.71M 2.23M 27.82M 2.21M 2.16M 96.16M 461K 406K 378K 347K 651K 44.25M 660K 4.49M 1.75M 21.85M 1.73M 1.69M 75.53M
Net income -2.38M -2.09M -1.95M -1.79M -3.36M -228M -3.4M -23.14M -9.04M -113M -8.93M -8.74M -389M -10.6M -9.32M -8.68M -7.97M -14.96M -1.02B -15.16M -103M -40.28M -502M -39.8M -38.95M -1.74B
Net Debt 1.42M 1.25M 1.17M 1.07M 2.01M 137M 2.04M 13.86M 5.41M 67.45M 5.35M 5.23M 233M -1.14M -999K -930K -854K -1.6M -109M -1.62M -11.05M -4.32M -53.8M -4.27M -4.17M -186M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
28/07/26 USD 1.590 -5.36% 4,166
24/07/26 USD 1.680 +5.00% 3,269
23/07/26 USD 1.600 -3.44% 6,667
22/07/26 USD 1.657 -1.37% 5,651
21/07/26 USD 1.680 -1.75% 3,315
  1. Stock Market
  2. Stocks
  3. POSC Stock